Bain Capital is set to acquire Mitsubishi Tanabe Pharma Corporation (Tanabe Pharma) in a carve-out transaction from Mitsubishi Chemical Group Corporation. The deal, led by Bain Capital’s Private Equity teams in Asia and North America together with the firm’s Life Sciences team, values the business at approximately JPY 510 billion (USD 3.3 billion). The transaction is expected to close in the third quarter of 2025.
Bain Capital’s Healthcare Expertise
Bain Capital’s global Healthcare platform has extensive experience supporting the growth and innovation of global pharmaceutical companies. This includes notable investments in Aiolos Bio (now part of GSK), Avistone Pharmaceuticals, Cardurion Pharmaceuticals, Cerevel Therapeutics (now part of AbbVie), Kailera Therapeutics, Stada, Tenacia Biotechnology, and Timberlyne Therapeutics. The firm is also a leading investor and partner to businesses across Japan, with over 70 investment professionals who have made more than 37 investments since establishing its Tokyo office in 2006.
Future Outlook
With this acquisition, Bain Capital aims to leverage its expertise in the healthcare sector to drive growth and innovation at Tanabe Pharma. The deal underscores Bain Capital’s commitment to supporting the development of pharmaceutical companies and enhancing their global market presence.-Fineline Info & Tech
